LOAMS
CHRS icon

Lombard Odier Asset Management (Switzerland)’s Coherus Oncology CHRS Stock Holding History

Lombard Odier Asset Management (Switzerland)’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-75,000
Closed -$2.11M – 359
2016
Q4 		$2.11M Sell
75,000
-25,000
-25% -$700K 0.53% 47
2016
Q3 		$2.68M Sell
100,000
-9,664
-9% -$264K 0.64% 32
2016
Q2 		$1.85M Buy
+109,664
New +$2.06M 0.25% 66

Other funds holding CHRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Lombard Odier Asset Management (Switzerland)'s CHRS Position: Q1 2017 in Review

Lombard Odier Asset Management (Switzerland) sold out of Coherus Oncology (CHRS) in Q1 2017, closing a stake of 75,000 shares — an estimated $2.11M sold.

Lombard Odier Asset Management (Switzerland) first reported a position in CHRS in Q2 2016 and held it in 3 quarters. The position peaked at $2.68M in Q3 2016. 109 funds tracked by Wall St. Rank hold CHRS as of Q1 2017.

  • Lombard Odier Asset Management (Switzerland) reported no remaining Coherus Oncology position as of Q1 2017 after selling out during the quarter.
  • Lombard Odier Asset Management (Switzerland) sold 75,000 Coherus Oncology shares in Q1 2017, an estimated $2.11M.
  • Lombard Odier Asset Management (Switzerland) first reported a position in Coherus Oncology in Q2 2016 and held it in 3 quarters.
  • Lombard Odier Asset Management (Switzerland)'s Coherus Oncology position peaked at $2.68M in Q3 2016.
  • 109 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2017.

Based on Lombard Odier Asset Management (Switzerland)'s 13F filing for Q1 2017, filed 15 May 2017.